Literature DB >> 19191850

Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus.

Ryo Takagawa1, Chikara Kunisaki, Hirochika Makino, Takashi Kosaka, Hidetaka A Ono, Hirotoshi Akiyama, Hiroshi Shimada.   

Abstract

We retrospectively investigated the efficacy of a chemoradiotherapy regimen using daily low-dose cisplatin and continuous 5-fluorouracil infusion in 71 registered patients with unresectable esophageal cancer. The overall response rate (complete response plus partial response) was 59%. The major toxicities observed were leukopenia and anorexia. The 1- and 3-year overall survival rates were 54.6% and 18.4%, respectively. A low preoperative C-reactive protein level was found to be associated with a good response. The pretreatment performance status and response results were both shown to be prognostic factors for overall survival. These findings confirmed that the chemoradiotherapy regimen had curative potential for unresectable esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191850     DOI: 10.1111/j.1442-2050.2008.00935.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  4 in total

1.  Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Nobuhiro Tsuchiya; Chikara Kunisaki; Sho Sato; Yusaku Tanaka; Kei Sato; Jun Watanabe; Kazuhisa Takeda; Takashi Kosaka; Hirotoshi Akiyama; Itaru Endo
Journal:  Langenbecks Arch Surg       Date:  2022-03-01       Impact factor: 2.895

2.  Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer.

Authors:  Ichiro Ogino; Shigenobu Watanabe; Noriaki Iwahashi; Masami Kosuge; Kentaro Sakamaki; Chikara Kunisaki; Kazuo Kimura
Journal:  Strahlenther Onkol       Date:  2016-02-16       Impact factor: 3.621

3.  Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).

Authors:  Masayuki Shinoda; Nobutoshi Ando; Ken Kato; Satoshi Ishikura; Hoichi Kato; Yasuhiro Tsubosa; Keiko Minashi; Hiroshi Okabe; Yusuke Kimura; Tatsuyuki Kawano; Shin-Ichi Kosugi; Yasushi Toh; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Cancer Sci       Date:  2015-03-09       Impact factor: 6.716

Review 4.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.